- Home
- / Blueprint Medicines
Blueprint Medicines
Stock Price
$83.4
2024-10-29
Market Capitalization
$5.3 B
2024-10-29
Revenue
$508.8 M
FY, 2024
Blueprint Medicines Summary
Company Summary
- Overview
- Blueprint Medicines is a biopharmaceutical company engaged in developing therapies for allergy, inflammation, and oncology/hematology. It offers medicines such as AYVAKIT (avapritinib) for gastrointestinal stromal tumors and systemic mastocytosis, and GAVRETO (pralsetinib), and is developing other drug candidates. The company provides products for healthcare providers treating mast cell disorders and oncology/hematology conditions.
- Type
- Public
- Status
- Active
- Founded
- 2011
- HQ
- Cambridge, MA, US | view all locations
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Andrew Law, Director, Corporate Communications
Percy Carter, Chief Scientific Officer
Kate Haviland, Director
LocationsView all
4 locations detected
Cambridge, MA HQ
United States
45 Sidney St
Amsterdam, NH
Netherlands
Gustav Mahlerplein 2
Lugano, TI
Switzerland
Via Emilio Bossi 6
Zug, ZG
Switzerland
Baarerstrasse 8
Blueprint Medicines Financials
Summary Financials
- Revenue (Q1, 2025)
- $149.4M
- Gross profit (Q1, 2025)
- $146.6M
- Net income (Q1, 2025)
- $496.0K
- Cash (Q1, 2025)
- $122.2M
- Enterprise value
- $5.4B